These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 24184236)
1. With age comes wisdom: is this true for platelets? Bonello L; Frère C; Paganelli F; Laine M J Am Coll Cardiol; 2014 Feb; 63(6):518-9. PubMed ID: 24184236 [No Abstract] [Full Text] [Related]
2. Response to letter regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction". Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos K; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G Circ Cardiovasc Interv; 2013 Apr; 6(2):e29. PubMed ID: 23591428 [No Abstract] [Full Text] [Related]
3. Letter by Grove and Kristensen regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction". Grove EL; Kristensen SD Circ Cardiovasc Interv; 2013 Apr; 6(2):e28. PubMed ID: 23591427 [No Abstract] [Full Text] [Related]
4. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. Perl L; Lerman-Shivek H; Rechavia E; Vaduganathan M; Leshem-Lev D; Zemer-Wassercug N; Dadush O; Codner P; Bental T; Battler A; Kornowski R; Lev EI J Am Coll Cardiol; 2014 Feb; 63(6):513-7. PubMed ID: 24148715 [TBL] [Abstract][Full Text] [Related]
5. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985 [TBL] [Abstract][Full Text] [Related]
6. [Differentiated antiplatelet therapy for acute coronary syndromes]. Schäfer A; Arntz HR; Boudriot E; Garlichs C; Hoffmann S; Ince H; Klingenheben T; Weil J; Zugck C; Helms TM; Silber S Dtsch Med Wochenschr; 2014 Jan; 139(4):152-8. PubMed ID: 24430955 [TBL] [Abstract][Full Text] [Related]
7. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891 [TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030 [TBL] [Abstract][Full Text] [Related]
9. Ticagrelor or prasugrel for pre-hospital protocols in STEMI? Fournier N; Toesca R; Bessereau J; Champenois A; Mazille A; Luigi S; Yvorra S; Paganelli F; Brun PM; Michelet P; Meyran D; Auffray JP; Bonello L Int J Cardiol; 2013 Oct; 168(4):4566-7. PubMed ID: 23871340 [No Abstract] [Full Text] [Related]
10. Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. Cuisset T; Cayla G; Quilici J; Pankert M; Deharo P; Bonnet G; Grosdidier C; Beguin S; Morange P; Bonnet JL; Alessi MC Int J Cardiol; 2013 Oct; 168(3):2988-9. PubMed ID: 23642612 [No Abstract] [Full Text] [Related]
11. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544 [TBL] [Abstract][Full Text] [Related]
12. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). Brener SJ; Oldroyd KG; Maehara A; El-Omar M; Witzenbichler B; Xu K; Mehran R; Gibson CM; Stone GW Am J Cardiol; 2014 May; 113(9):1457-60. PubMed ID: 24630789 [TBL] [Abstract][Full Text] [Related]
13. Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. Deharo P; Pankert M; Bonnet G; Quilici J; Bassez C; Morange P; Alessi MC; Bonnet JL; Cuisset T Int J Cardiol; 2014 Oct; 176(3):1200-2. PubMed ID: 25156857 [No Abstract] [Full Text] [Related]
14. [Myocardial infarction: Role of new antiplatelet agents]. Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430 [TBL] [Abstract][Full Text] [Related]
15. [Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction]. Koziński M; Grześk G; Kubica J Kardiol Pol; 2012; 70(2):206-12. PubMed ID: 22427098 [No Abstract] [Full Text] [Related]
16. Antiplatelet therapy beyond 2012: role of personalized medicine. Tantry US; Budaj A; Gurbel PA Pol Arch Med Wewn; 2012; 122(6):298-305. PubMed ID: 22751292 [TBL] [Abstract][Full Text] [Related]